Unraveling LncRNA GAS5 in Atherosclerosis: Mechanistic Insights and Clinical Translation
Biology · 13.06.2025 · 14 (6) · 697
DOI: 10.3390/biology14060697 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biology, online erschienen am 13.06.2025. Verfasst von Yu Wei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Vascular Biology and Translational Medicine, Medical School, Hunan University of Chinese Medicine, Changsha 410208, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, the Science and Technology Innovation Program of Hunan Province, the Hunan Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
Atherosclerosis, a chronic inflammatory disease driving cardiovascular events, involves complex molecular networks where long non-coding RNAs (lncRNAs) are key regulators. This review synthesizes current knowledge on lncRNA Growth Arrest-Specific 5 (GAS5) in atherosclerosis, covering its expression, multifaceted roles in vascular cells, and molecular mechanisms. GAS5 is significantly upregulated in atherosclerotic plaques, exerting complex, cell-specific effects on vascular smooth muscle cells, macrophages, and endothelial cells. GAS5 modulates crucial pathophysiological processes like cell proliferation, apoptosis, inflammation, lipid metabolism, and foam cell formation, primarily by acting as a competing endogenous RNA (ceRNA) and through direct protein interactions. While promising as a biomarker, circulating GAS5 levels require further validation. Therapeutic strategies targeting GAS5, including antisense oligonucleotides (ASO) and small-molecule compounds, are under investigation. In conclusion, lncRNA GAS5 is a critical regulatory node in atherosclerosis pathobiology, offering significant opportunities for novel diagnostic and therapeutic interventions. Further research is vital to elucidate its intricate roles and translate these findings into clinical applications for atherosclerotic cardiovascular disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Vascular Biology and Translational Medicine, Medical School, Hunan University of Chinese Medicine, Changsha 410208, China.
- Key Laboratory for Quality Evaluation of Bulk Herbs of Hunan Province, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
- Basic Research Center of Integrated Chinese and Western Medicine on Prevention and Treatment of Vascular Diseases, Medical School, Hunan University of Chinese Medicine, Changsha 410208, China.
ORCID-Profile: Yu Wei, Quanye Luo, Xiang Li, Qinhui Tuo, Wen Chen
Förderung
- the National Natural Science Foundation of China
- the Science and Technology Innovation Program of Hunan Province
- the Hunan Provincial Natural Science Foundation of China
- the Department of Education of Hunan Province
- the Hunan Students Innovation and Entrepreneurship Training Program
- the Undergraduate Research and Innovation Fund of Hunan University of Chinese Medicine
- National Natural Science Foundation of China
- Science and Technology Innovation Program of Hunan Province
Zitieren
APA
Wei, Y., Luo, Q., Li, X., Liu, X., Yang, Z., Tuo, Q., & Chen, W. (2025). Unraveling LncRNA GAS5 in Atherosclerosis: Mechanistic Insights and Clinical Translation. Biology, 14(6), 697. https://doi.org/10.3390/biology14060697
Vancouver
Wei Y, Luo Q, Li X, Liu X, Yang Z, Tuo Q, et al. Unraveling LncRNA GAS5 in Atherosclerosis: Mechanistic Insights and Clinical Translation. Biology. 2025;14(6):697. doi:10.3390/biology14060697
BibTeX
@article{Wei2025,
author = {Wei, Yu and Luo, Quanye and Li, Xiang and Liu, Xi and Yang, Zheyu and Tuo, Qinhui and Chen, Wen},
title = {Unraveling LncRNA GAS5 in Atherosclerosis: Mechanistic Insights and Clinical Translation},
journal = {Biology},
year = {2025},
volume = {14},
number = {6},
pages = {697},
doi = {10.3390/biology14060697}
}
EUVIMED